B+
Bull case
0%
Probability
Target price
$220.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
BIIB
BiogenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull read is that Q1 showed better-than-feared core execution: revenue and EPS grew year over year, growth products remained strong, LEQEMBI sales kept scaling, and management framed Apellis plus felzartamab as portfolio actions that can improve the medium-term growth mix. The dated May 24 LEQEMBI IQLIK decision adds a near-term regulatory hook.
Posture
Mixed
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
2026 non-GAAP EPS guidance was cut to $14.25-$15.25 from $15.25-$16.25, excluding Apellis, due to acquired IPR&D charges tied to business-development activity, with about $0.80 of the impact expected in Q2. [#8-K-2026-04-29]
Momentum
47
Value
67
Sentiment
56
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $203.00 · Bull $220.00 · Bear $170.00Analysis 2026-04-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $239.28
Why
Momentum47 · Δ7d +11.5
Value67 · Δ7d -0.0
Sentiment56 · Δ7d +7.4
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +7.4.
Contradictions & invalidation
- • 2026 non-GAAP EPS guidance was cut to $14.25-$15.25 from $15.25-$16.25, excluding Apellis, due to acquired IPR&D charges tied to business-development activity, with about $0.80 of the impact expected in Q2. [#8-K-2026-04-29]
- • Full-year 2026 revenue is still expected to decline by a mid-single-digit percentage year over year, showing that legacy-product pressure remains meaningful despite growth-product strength. [#8-K-2026-04-29]
- • The bear read is that the quarter did not remove the main debate: 2026 revenue is still guided down a mid-single-digit percentage, the EPS outlook was cut, some Q1 support came from inventory/allowance timing and accelerated manufacturing activity, and Apellis adds financing and integration risk before investors see clean underlying growth.
Catalyst clock
2026-05-06
Q1 beat offsets part of the guidance cut in near-term tape digestion
Lead driver: Sentiment · See AI snapshot
Momentum
47
9% active weight
Current posture
7d trendImproving
Δ7d
+11.5
Δ21d
-9.4
Value
67
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.9
Sentiment
56
62% active weight
Current posture
7d trendImproving
Δ7d
+7.4
Δ21d
+2.1
Why this grade
Composite grade C. Momentum 46.6 / Value 66.5 / Sentiment 56.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-29. Scenario method
Most likely
B
Base case
0%
Probability
Target price
$203.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$170.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$30.9B
Beta
0.16
Shares Out
147.75M
P/E (TTM)
15.9
P/S (TTM)
2.55
P/FCF (TTM)
11.33
Rev YoY
+2.4%
EPS YoY
-84.8%
Gross Margin
+64.3%
Op Margin
+19.5%
Net Debt
$2.84B
Current Ratio
1.87
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data